ESSA Pharma Inc. Shareholder/Analyst Call Transcript

ESSA Pharma Inc. holds a shareholder/analyst call to discuss their company. The call is recorded for transparency. No specific information is provided in the given transcript.

ESSA Pharma Inc. (NASDAQ: EPIX) held a shareholder/analyst call on October 3, 2025, to discuss the company's ongoing activities and future plans. The call was recorded for transparency and was open to registered shareholders, option holders, warrant holders, and registered proxy holders who voted electronically through the Computershare system. The meeting was held virtually to ensure accessibility and efficiency, with voting conducted online to maintain the integrity of the process.

During the call, David Parkinson, President and Chief Executive Officer of ESSA, acted as the chair and provided an overview of the meeting's rules and procedures. The meeting's focus was on the company's recent developments, including its application to the Supreme Court of British Columbia for an amended interim order regarding its business combination agreement with XenoTherapeutics Inc. ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order^[2]. This agreement involves Xeno acquiring all of ESSA's issued and outstanding common shares, with the transaction expected to be completed on the anticipated terms and timing.

The call also addressed the potential risks and uncertainties associated with the transaction, including regulatory approvals, potential litigation, and the impact on the company's business operations. ESSA's management acknowledged the importance of transparency and provided detailed information about the transaction's progress and the company's plans to mitigate potential risks.

The meeting was conducted in a professional and accessible manner, ensuring that all stakeholders had the opportunity to participate and ask questions. The call highlighted ESSA's commitment to transparency and its efforts to navigate the complex legal and regulatory landscape surrounding its business combination with XenoTherapeutics Inc.